ライフサイエンスコーパス: radiation oncology

1 representatives from surgical, medical, and radiation oncology.

2 ften assumed in the chemistry and physics of radiation oncology.

3 assist clinical tumor volume delineation in radiation oncology.

4 mor biology into clinical decision making in radiation oncology.

5 context-aware target volume delineation for radiation oncology.

6 r and therefore is of clinical relevance for radiation oncology.

7 al pillars of medical oncology, surgery, and radiation oncology.

8 ex from 2000 to 2019 among senior faculty in radiation oncology.

9 cer Foundation, and the American Society for Radiation Oncology.

10 g the use of imaging for therapy planning in radiation oncology.

11 design genomically-guided clinical trials in radiation oncology.

12 design genomically-guided clinical trials in radiation oncology.

13 ges of imaging-based treatment adaptation in radiation oncology.

14 ions of nanotechnology within the context of radiation oncology.

15 he various applications of nanotechnology in radiation oncology.

16 uropsychology, ophthalmology, pathology, and radiation oncology.

17 the banked clinical successes in gynecologic radiation oncology.

18 y and Oncology who had completed training in radiation oncology.

19 tem changes on the practice of radiology and radiation oncology.

20 A total of 351 oncologists (35.0%) worked in radiation oncology, 344 (34.3%) in medical oncology, 186

21 Fifteen percent of positions were in radiation oncology, 52% in general diagnostic radiology,

22 rking Group aimed to assess the inclusion of radiation oncology alongside haematology and oncology, p

23 niversity School of Medicine's Department of Radiation Oncology and Cancer Institute.

24 a brief update of the latest developments in radiation oncology and describes the current best practi

25 sent a framework for the value discussion in radiation oncology and identify approaches for attaining

26 riod (several days), which is beneficial for radiation oncology and imaging.

27 l Institutes of Health, American Society for Radiation Oncology and Melanoma Research Alliance, and W

28 s a valuable resource for patient queries in radiation oncology and other medical fields.

29 ology journals, with under-representation of radiation oncology and other specialties, such as diagno

30 ng both the American Society for Therapeutic Radiation Oncology and Phoenix criteria.

31 neration to advance preclinical research for radiation oncology and precision medicine.

32 opment and implementation of AI platforms in radiation oncology and provide our perspective on how th

33 targeting of lesions, with implications for radiation oncology and surgical planning.

34 f Radiology (ACR) In-Training Examination in Radiation Oncology and the American Board of Radiology (

35 mbers of the European Society of Therapeutic Radiation Oncology and the American Society for Therapeu

36 n Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a li

37 n Expert Panel of medical oncology, surgery, radiation oncology, and advocacy experts to conduct a li

38 e role of surgery in relation to medical and radiation oncology, and argue that surgery must be inclu

39 colleagues in neuro-oncology, neurosurgery, radiation oncology, and neuropathology.

40 cology, surgical oncology, medical oncology, radiation oncology, and nursing was formed and tasked wi

41 ting medical hematology/oncology, radiology, radiation oncology, and pathology to review currently us

42 y of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology con

43 y of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology pan

44 y of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology.

45 Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to

46 2 to 2018 from 13 general oncology/medicine, radiation oncology, and surgical journals were included

47 f Clinical Oncology and American Society for Radiation Oncology annual meetings from January 1, 2010,

48 mains the main molecular imaging modality in radiation oncology applications.

49 rs or older and presenting for their initial radiation oncology appointment were asked to complete a

50 the ASTRO guideline, published in Practical Radiation Oncology, are clear, thorough, and based on th

51 Radiation oncology as a specialty has recently become a

52 A multidisciplinary American Society for Radiation Oncology-ASCO-Society of Surgical Oncology tas

53 The American Society for Radiation Oncology (ASTRO) guideline content and recomme

54 Surgical Oncology (SSO)/American Society for Radiation Oncology (ASTRO) guideline on surgical margins

55 American Society of Radiation Oncology (ASTRO) has developed a guideline on

56 The American Society for Radiation Oncology (ASTRO) produced an evidence-based gu

57 Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based gu

58 Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based gu

59 Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based gu

60 The American Society for Radiation Oncology (ASTRO) produced an evidence-based gu

61 as been endorsed by the American Society for Radiation Oncology (ASTRO).

62 he American Board of Radiology (ABR) Written Radiation Oncology Board Examination.

63 sed, controlled SPPORT trial was done at 283 radiation oncology cancer treatment centres in the USA,

64 In this study, radiation oncology care provided by fully remote clinici

65 is study included 2817 patients who received radiation oncology care with fully remote physician mana

66 er in-person or remote telehealth visits for radiation oncology care.

67 onducted within all 18 urology centers and 7 radiation oncology centers in the Piemonte and Valle d'A

68 of hypofractionation is gaining momentum in radiation oncology centres, enabled by recent advances i

69 ort study conducted at a university hospital radiation oncology clinic.

70 trials are highlighted, with an emphasis on radiation oncology clinical trials.

71 y and Oncology, and the American Society for Radiation Oncology collaboratively developed evidence-ba

72 Despite tremendous gains, the radiation oncology community continues to struggle with

73 18F-FDG PET offers the radiation oncology community the ability to incorporate

74 ial and catalysed by the need for the global radiation oncology community to unite during the COVID-1

75 rding to the American Society of Therapeutic Radiation Oncology Consensus Statement, and toxicity was

76 ings may be especially relevant for Medicare radiation oncology coverage policies.

77 dy if they had visits with clinicians in the radiation oncology department within 5 weeks of diagnosi

78 res, through the cooperation of six academic radiation oncology departments, for residents-in-trainin

79 a trends database for all U.S. radiology and radiation oncology departments.

80 prostate carcinoma who were referred to the radiation oncology division between January 1, 1994, and

81 023-01541-3), Journal of Medical Imaging and Radiation Oncology (DOI 10.1111/1754-9485.13612), Canadi

82 an Radiology, Journal of Medical Imaging and Radiation Oncology (DOI 10.1111/1754-9485.13842), Journa

83 This review will primarily focus on radiation oncology examples, will address issues regardi

84 are units, positron emission tomography, and radiation oncology facilities is associated with greater

85 pread rapidly in both academic and community radiation oncology facilities.

86 Radiation oncology fellowship graduates often had poorer

87 ls have been used in many different areas of radiation oncology for imaging and treatment planning, a

88 ntextualise developments within the field of radiation oncology for the non-radiation oncologist.

89 artments of radiology and six departments of radiation oncology from areas with low, medium, or high

90 esearch Programs Committee and Department of Radiation Oncology, Gail and Joseph Gassner Development

91 Practice (ESTRO-ACROP), PERYTON, Faculty of Radiation Oncology Genito-Urinary Group (FROGG), and Rad

92 particularly transformative applications in radiation oncology given the multifaceted and highly tec

93 rvey of surviving participants in the Proton Radiation Oncology Group (PROG) 9509--a randomized trial

94 448 features (35%) were found stable for the radiation oncology group and 214 features (16%) were sta

95 ed phase II clinical trial, the Trans Tasman Radiation Oncology Group compared single- versus multifr

96 ures, but ICCs were generally higher for the radiation oncology group than for the radiology group.

97 he authors surveyed diagnostic radiology and radiation oncology groups regarding finances, workload,

98 A recent American Society for Radiation Oncology guideline and systematic review, prev

99 cology convened a panel of medical oncology, radiation oncology, guideline implementation, and advoca

100 (ASCO) convened a panel of medical oncology, radiation oncology, guideline implementation, and advoca

101 HRRs with more vulnerable networks for radiation oncology had a higher percentage of beneficiar

102 urate patient-clinician communication within radiation oncology has yet to be explored.

103 the space radiation environment and used in radiation oncology, has potentially greater carcinogenic

104 Advances in radiation oncology have been made on three major fronts:

105 and intensity modulated radiation therapy in radiation oncology have resulted in substantial changes

106 In radiation oncology, hyperthermia is known to radiosensit

107 priority areas, including surgical oncology, radiation oncology, imaging, health systems and health d

108 aid in optimizing the efficacy of multimodal radiation oncology in combination with post-irradiation

109 s when used alongside medical, surgical, and radiation oncology in the care of cancer patients.

110 one of the most important success stories in radiation oncology in the latter half of the twentieth c

111 The advancements in radiation oncology in the past 50 years in the United St

112 Finally, we review new frontiers in radiation oncology, including advances within the metast

113 ive cohort study was conducted at 6 academic radiation oncology institutions, 5 in Canada and 1 in Sc

114 Radiation oncology is a cornerstone in the treatment of

115 Radiation oncology is essential in the management of bre

116 However, the field of radiation oncology is still one of the most poorly under

117 Theragnostic imaging for radiation oncology is the use of molecular and functiona

118 y and Oncology, and the American Society for Radiation Oncology jointly developed evidence-based guid

119 A forum of radiation oncology lymphoma leaders from the National Cl

120 The Department of Radiation Oncology, Mayo Clinic, Minnesota and Arizona,

121 ayo Clinic, Rochester, MN, the Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, USA, and t

122 The Department of Radiation Oncology, Mayo Clinic, Rochester, MN, the Depa

123 istration are calculated and provided to the radiation oncology medical physicists for combination th

124 torhinolaryngology or head and neck surgery, radiation oncology, medical oncology, and clinical oncol

125 iewed by a multidisciplinary group (surgery, radiation oncology, medical oncology, and pathology) and

126 levant disciplines (gynaecological oncology, radiation oncology, medical oncology, and pathology).

127 iplines that includes head and neck surgery, radiation oncology, medical oncology, medical imaging, c

128 American Society of Radiation Oncology model policies were used to classify

129 ies are also well suited for applications in radiation oncology, nanomaterials have been used in many

130 anel of medical oncology, surgical oncology, radiation oncology, neuroradiology, pathology, and patie

131 medical oncology, neuro-oncology, neurology, radiation oncology, neurosurgery, and ophthalmology met

132 Furthermore, strong collaboration between radiation oncology, nuclear medicine/radiology, and medi

133 With three radiation oncology observers and three radiology observe

134 Radiation oncology observers showed a higher average DSC

135 ciplines of otolaryngology, palliative care, radiation oncology, oncology, nutrition, speech, and phy

136 charged home after a week and referred for a radiation oncology opinion.

137 This difference was not seen for radiation oncology or surgical oncology journals.

138 Panel of medical oncology, thoracic surgery, radiation oncology, pathology, cancer genetics, and advo

139 ng plays a central role in the management of radiation oncology patients.

140 sis should be placed on adequate training of radiation oncology personnel to understand the potential

141 which are radiodiagnosis, nuclear medicine, radiation oncology, physical medicine and rehabilitation

142 mage interpretation without direct access to radiation oncology planning software and data.

143 this systematic review and meta-analysis of radiation oncology PR of contoured targets, radiologist

144 iotherapy and Oncology-Advisory Committee on Radiation Oncology Practice (ESTRO-ACROP), PERYTON, Facu

145 iotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus state that moderat

146 In current radiation oncology practice, treatment protocols are pre

147 The MROQC includes academic and community radiation oncology practices across Michigan.

148 Radiation oncology practices use a suite of dedicated so

149 questionnaire was mailed to all graduates of radiation oncology programs and to a stratified, random

150 thology, genetics, and surgical, medical and radiation oncology providers.

151 Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncolo

152 Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, community oncology, resea

153 Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary, radiology, primary care,

154 tal of 29 practices enrolled in the Michigan Radiation Oncology Quality Consortium quality initiative

155 Of the 115 radiation oncology questions retrieved from 4 profession

156 ical oncology, surgical oncology, pathology, radiation oncology, radiology, and translational researc

157 n Expert Panel of medical oncology, surgery, radiation oncology, radiology, pathology, and advocacy e

158 anel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient ad

159 American experts from surgical, medical, and radiation oncology, radiology, pathology, gastroenterolo

160 of experts across urology, medical oncology, radiation oncology, radiology, pathology, translational

161 ropeen de Curietherapie European Society for Radiation Oncology recommendations.

162 rs being cost of the radiotherapy plaque and radiation oncology-related expenses.

163 Whether MA meets the value proposition for radiation oncology requires further investigation.

164 e Andrew Sabin Family Fellowship, Center for Radiation Oncology Research, Sheikh Ahmed Center for Pan

165 surgery, pulmonology, medical oncology, and radiation oncology reviewed all nodules and coordinated

166 favored the referral service vs the primary radiation oncology service (44% vs 26%; P = .01), but th

167 increasing presence of molecular imaging in radiation oncology, special emphasis should be placed on

168 Further advances in the palliative radiation oncology subspecialty will require integration

169 onvened an Expert Panel of medical oncology, radiation oncology, surgical oncology, gastroenterology,

170 onvened an Expert Panel of medical oncology, radiation oncology, surgical oncology, gastroenterology,

171 e of experts in medical oncology, pathology, radiation oncology, surgical oncology, guideline impleme

172 ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care,

173 l of integrative oncology, medical oncology, radiation oncology, surgical oncology, palliative oncolo

174 l of integrative oncology, medical oncology, radiation oncology, surgical oncology, palliative oncolo

175 linicians in the fields of medical oncology, radiation oncology, surgical oncology, survivorship, and

176 patient received a message from the primary radiation oncology team or the referral service.

177 mor dose is lower than that used in external radiation oncology, the effectiveness of treatment is qu

178 on is arguably the greatest challenge facing radiation oncology, the greatest impact that molecular i

179 the integration of mathematical models into radiation oncology to simulate individual patient tumor

180 codes and Fermi-Eyges semiemprical models in radiation oncology treatment planning.

181 raphy), imaging diagnostics (CT), treatment (radiation oncology), treatment (surgery), and health-car

182 Radiation oncology utilization rate added 11 procedures

183 Klopp et al, published in 2014 in Practical Radiation Oncology, was reviewed for developmental rigor

184 nternational clinical experts in gynecologic radiation oncology were invited; 39 (62%) accepted and c

185 ayer-denied cases, most insurance denials in radiation oncology were ultimately approved on appeal; h

186 nd the greatest disparities were observed in radiation oncology, with variations of 62 times by count

187 a result of the aging US population, but the radiation oncology workforce has not been studied.

188 Group of Surgical Oncology/Working Group of Radiation Oncology/Working Group of Medical Oncology of